MCA logo

PUBLIC PORTAL

invest selangor

MEDICALLY REVIEWED

FDA Approves Omisirge Cell Therapy to Reduce Infection Risk in Patients with Hematologic Malignancies

Chemotherapy
Omisirge is used in adults and children aged 12+ for cord blood transplant after myeloablative conditioning in hematologic malignancies.

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: